Sunlight and Skin Health


Sunlight and skin health

Making a Friend out of a Foe

By Johanne Kloster Ellingsen (ShareLab Staff Writer), published March 3, 2022

Most of us have repeatedly been reminded of the importance of protecting our skin from the damaging rays of sunlight. Still, more than 50% of Norwegians over 50 have sun-damaged skin, says Oscar Solér, Managing Director of the Oslo-based start-up 3Skin. At 3Skin they are aiming to flip the script, as they have been developing solutions to reduce phototoxic effects on the skin with the help from the very same agent that damaged the skin in the first place: the sun.

The reasoning behind the name 3Skin is two-fold, Oscar explains. Firstly, the name is after the three founders Ana Maria Solér, Trond Warloe and Qian Peng, all MDs, and experts within the technology the company is built on, so-called photodynamic therapy. Photodynamic therapy is a clinically established modality against a range of cancers, as well as various forms of skin-damage. The founders of 3Skin were heavily involved in developing photodynamic treatments against skin damage at the Oslo University Hospital in the 1990s, setting the stage for its wide-spread applications 30 years later. However, the founders reasoned that the technology could also be used to prevent the formation of the skin damage. 3Skin was born in 2016 and is currently working on developing a sunscreen that, with the help from the sun, does just that.

In short, photodynamic therapy uses a combination of a photosensitising compound and light to specifically attack and kill damaged cells. In the 3Skin’s sunscreen, 5-aminolevulinic acid (5-ALA), a naturally occurring amino acid, is used. Once taken up by the skin cells, 5-ALA forms the photosensitising protoporphyrin-IX which, in a high concentration and upon red light exposure, will induce cell death. Crucially, sun-damaged cells (like cancerous cells) have a higher production of 5-ALA-derived protoporphyrin-IX leading to selective cell death of damaged cells in the skin after light exposure. The damaged cells will then be replaced by new, healthy cells, a process called skin rejuvenation. This process also stimulates collagen production in the lower layer of the skin, increasing skin elasticity.

That leads us to the second reason for the company name, the three biological effects of its sunscreen: protection, rebuilding, and stimulation. Using a low dose of 5-ALA in combination with vitamin D3 and protective agents against damaging sun radiation, the 3Skin’s sunscreen protects against sun, rebuilds the skin with new and healthy cells, and stimulates collagen production. And the ingenious part, the light used to activate 5-ALA-induced protoporphyrin-IX leading to removal of damage cells and induction of collagen production comes from the sun. Thus, enjoying the sun while using the 3Skin’s sunscreen has the happy side-effect of not only preventing photo-damage, but also reducing wrinkles resulting in a skin that appears more youthful.

Having found its own niche within the photodynamic therapy space, the company, now run by Oscar, the son of one of the founders who stumbled into the family business while studying industrial design, is hoping to get a product to the market within the coming years. The vision is to further develop products that prevent, and in the future potentially treat, photodamaged skin. All are while enjoying sunshine. Who said you can’t have the cake and eat it?


About 3Skin and ShareLab

3Skin is based at ShareLab (Oslo, Norway). ShareLab offers fully equipped and serviced wet labs for startups and industrial partners, as well as a community of industry experts and biotech entrepreneurs. The laboratory is located at Oslo Science Park amid Norwegian institutions like University of Oslo, Oslo University Hospital, SINTEF, and a range of life science companies. ShareLab is non-profit and will reinvest profits in cutting edge laboratories and industrial knowhow to help fuel life science.






Ledig stilling for studentskribent


Ledig deltidsstilling for student

Vil du skrive om vitenskap og innovasjon?

Published October 26, 2021

ShareLab er en labinkubator for livsvitere i Forskningsparken i Oslo. Laboratoriet huser i dag 28 selskaper med 70 livsvitere og entreprenører som har som mål å skape nye produkter innen diagnostikk, medisin, veterinærmedisin, landbruk og energi.

Vi søker nå etter en skriveglad student med bakgrunn innen biologi, biokjemi, farmasi eller medisin for å skrive artikler og intervjuer for ShareLab. Du bør ha tilbakelagt minst to studieår og skrive flytende norsk og engelsk på høyt nivå. Jobben er timesbetalt og fleksibel. Vi tror omfanget vil være på rundt 3 timer i gjennomsnitt per uke.

Arbeidet vil gi deg trening i å formidle avansert teknologi, utvide ditt nettverk og gi deg innsikt i innovasjon og entreprenørskap innen livsvitenskapene.

Send CV, karakterutskrift og en halv side med en fiktiv artikkel til ShareLab innen 15. november 2021 via LinkedIn. Bruk denne LINK.


ShareLab Startup Show ’21


Meet our bioentrepreneurs

ShareLab Startup Show 2021

Published September 27, 2021

• Meet our most experienced founders
• Hear about our plans for the future
• Learn to know our community

Sharelab is a lab community embracing all entrepreneurs developing product in wet labs.  These startups will present:

  • Arxx Therapeutics - anti-S100A4 mabs for treatment of fibrosis
  • Beefutures - digital beehive
  • Caedo Oncology - anti-CD47 mabs for cancer treatment
  • Cenate - Silicon based nanotechnology for next generation batteries
  • CLEXbio - advanced tissue engineering
  • Corticalis - scaffolds for bone regeneration
  • Hemispherian - small molecule targeting brain cancer
  • Inhibio - antifouling technology
  • Marimetrics - aquaculture sensors
  • Norimmun - vaccines for animal health
  • Temogene - aquaculture genetics

Read More


A guru never calls himself a guru


New team member at ShareLab

A guru never calls himself a guru

Published September 20, 2021

ShareLab adds Lab Lead and entrepreneur-in-residence to the team

As of this month, the ShareLab team has been expanded with a new member: Tor Espen Stav-Noraas has a PhD in immunology and comes with several years of biotech experience from Thermo Fisher Scientific. He will take a leading role in moving ShareLab’s lab facilities and services to the next level, as well as assume the role of entrepreneur-in-residence.

Says Tor Espen “I love early discovery with a clear perception of the end-product in mind”. Cell therapy was Tor Espen’s key field at Thermo, while academic years were spent studying IL-33 and Notch pathways.

“The combination of his academic and industrial experience will no doubt be of great value to ShareLab members”, comments Esben A. Nilssen, managing partner at ShareLab, before continuing, “he will also help develop ideas into new biotech start-ups as part of his role as an entrepreneur-in-residence”.

We believe Tor Espen is our new biotech guru. Mind you, a guru would never call himself a guru.


Feel the pain, then push harder


Hemispherian Oncology

Feel the Pain, then Push Harder

Published February 26, 2020

It is a moment in every marathon race where you can either quit, fold, or say to yourself, ‘I can do this’. We know, it is a cheap trick to use sports lingo to describe entrepreneurship. However, in the case of Adam Robertson, Chief Scientific Officer and scientific founder of Hemispherian Oncology, it is more than tempting. It is necessary. Adam is a no-bullshit type with the stamina of a sleigh dog, his upbringing being far from winter and snow.

During boyhood years he was fed on Brunswick stew, peanut soup, and marble cake in Virginia, the birthplace of America. His father’s military assignment brought him to Guam for three years before he attended Virginia Tech and later University of North Carolina at Chapel Hill for doctoral work. It was, however, as a postdoctoral researcher and group leader at Oslo University Hospital he understood that academic life was really not for him. Another day, another paper. Adam wanted to feel the pain, push harder, make an impact. He invented a novel CRISPR-like technology called RACeR, but what finally made him pull out of academia was the discovery that a group of small molecules would selectively kill glioblastoma cells. Glioblastoma patients have a median survival of 15-16 months. It was a no brainer: he wanted to make an impact, he exited academia.

Hemispherian Oncology has been hand built and bootstrapped by Adam, his Swiss partner Zeno Albisser (CEO), and a small dedicated team of scientists. This year they will do a seed round, imagine what they can do with money. Back to the sports lingo. The marathon is not really about the running (or the running entrepreneur), it's about the shared struggle. You will not be surprised that Adam is a marathon runner both intellectually and as a matter of fact.

Adam Robertson will give the lunch seminar at ShareLab 5 March 2020 at 11 am titled ‘Glioblastoma: not licenced to kill’. The seminar is open to all interested. Bring your lunch. Coffee, tea, and pastry will be served. Check more details here

Sharelab favicon News

Lunch Seminar Program WS 2020


Lunch Seminar Program W/S 2020

Entreprenurial Science

Lunch seminars WS20

Published 13 December 2019

ShareLab's lunch seminar program is out. Biotech lovers are in for a real treat 

In 2020 we will take a full dive into the science underpinning our member companies. The first four seminars are dedicated to human drug og dx start-ups covering inflammation, Alzheimer, and cancer. Closer to summer we will be introduced to how stem cell research may render it possible to culture meat, while our last seminar in June is reserved for fish health and aquaculture. The title of the latter seminar is yet to be announced.

Bring your own lunch to ShareLab – we will serve coffee and drinks. All interested welcome. Seminars are held in our co-working space at Oslo Science Park unless otherwise announced. Please show interest by using our Facebook event page posted 3 weeks ahead of the seminar date.


IP Clinic at ShareLab


Dehns at ShareLab

IP Clinic

Published 27 September 2019

Do you struggle with your biotech IPR? Do not despair. European patent attorneys Dehns are running an IP clinic at ShareLab on 1st October 2019. 

Dehns are members of ShareLab and offer current and future members a helping hand. If you are in need, please send an email to


Everything You Always Wanted to Know About HPLC*


HPLC at ShareLab: scientists from member company Vaccibody having a ball.

Everything You Always Wanted to Know About HPLC*

*But Were Afraid to Ask

Published 6 May 2019

Would you like to separate, identify, or quantify components in a mixture? At SharaLab we have both analytical and preparative HPLC systems at you disposal. No or little experience? No, worries! Join our workshop 29 May and we will make you fly. 

The workshop is a collaboration between Matriks and ShareLab. We start off with a little theory before we head off to the lab to run some real samples. If you would like to run your own samples, you are welcome to join our community. Also, if you would like help with the first samples (or the whole campaign for that matter), we have HPLC experts ready to help you off the ground. Check out the program and sign up HERE. Other questions? Reach out via FaceBook's Messenger.

Something Fishy is Going On


Something Fishy is Going On

Published April 9 2019

How may life scientist help better control this biological risk in aquaculture?

ShareLab kicked off 2019 with an excursion to Bremnes Seashore’s fantastic hatchery at Trovåg and has since then spent time with the industry at every major aquaculture conference. We already have aquaculture startups within biofilm, lice vaccines, salmon genomics, and submersible pens. Going forward we would like to see DNA vaccines, pathogen bioinformatics, biological counter lice measures, and rapid diagnostic tests.


Bioprocessing: Stirred, But Not Shaken


Bioprocessing: Stirred, But Not Shaken

Published Descember 29th 2019

Do you want to give your shake flasks cultivation an extra boost? Then do not wait any longer and transfer to a bioreactor or fermenter. ShareLab will teach you how. Sign up for the workshop 6 February 2019.

The workshop is a collaboration between Eppendorf, SINTEF, and ShareLab. The workshop will kick off with a teach-in on the advantages and challenges of shaker cultures, before participants are introduced to bioreactors by Eppendorf experts. Bioreactors are not just about scaling up and scaling down, but also to gain control and enhance reproducibility. You probably know that bacteria, yeast, plant cells, insect cells and mammalian cells are cultured in bioreactors, but did you know that stems cells may also be cultured this way? Inga Marie Aasen from SINTEF will share great cases and work from her labs and after lunch there will be a hands-on demonstration of a bioreactor in ShareLabs. We will use the the Eppendorf BioFlo® 120 and the DASbox® as demonstration systems.

Challenges with you own culturing, fermentation or expression? No problem, bring your questions and consult the experts during the workshop.

Check out the program and sign up HERE.